Stephen D. Wiviott

66.9k total citations · 19 hit papers
206 papers, 37.8k citations indexed

About

Stephen D. Wiviott is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Stephen D. Wiviott has authored 206 papers receiving a total of 37.8k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Cardiology and Cardiovascular Medicine, 90 papers in Surgery and 30 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Stephen D. Wiviott's work include Antiplatelet Therapy and Cardiovascular Diseases (102 papers), Acute Myocardial Infarction Research (99 papers) and Lipoproteins and Cardiovascular Health (44 papers). Stephen D. Wiviott is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (102 papers), Acute Myocardial Infarction Research (99 papers) and Lipoproteins and Cardiovascular Health (44 papers). Stephen D. Wiviott collaborates with scholars based in United States, United Kingdom and Canada. Stephen D. Wiviott's co-authors include Sabina A. Murphy, Eugene Braunwald, Elliott M. Antman, Marc S. Sabatine, Deepak L. Bhatt, Carolyn H. McCabe, C. Michael Gibson, Lawrence A. Leiter, Robert P. Giugliano and Darren K. McGuire and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Stephen D. Wiviott

198 papers receiving 36.6k citations

Hit Papers

Prasugrel versus Clopidogrel in Patients with Acute Coron... 2004 2026 2011 2018 2007 2018 2011 2015 2013 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
    2007 4.4k citations Stephen D. Wiviott, Eugene Braunwald et al. New England Journal of Medicine profile →
  2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    2018 4.3k citations Stephen D. Wiviott, Marc P. Bonaca et al. New England Journal of Medicine profile →
  3. Standardized Bleeding Definitions for Cardiovascular Clinical Trials
    2011 2.9k citations Deepak L. Bhatt, Stephen D. Wiviott et al. Circulation profile →
  4. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    2015 2.9k citations Michael A. Blazing, Robert P. Giugliano et al. New England Journal of Medicine profile →
  5. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    2013 2.5k citations Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine profile →
  6. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
    2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet profile →
  7. Cytochrome P-450 Polymorphisms and Response to Clopidogrel
    2008 1.7k citations Jessica L. Mega, Stephen D. Wiviott et al. New England Journal of Medicine profile →
  8. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
    2011 1.3k citations Jessica L. Mega, Eugene Braunwald et al. New England Journal of Medicine profile →
  9. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine profile →
  10. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes
    2004 971 citations Michael A. Blazing, Stephen D. Wiviott et al. profile →
  11. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    2009 669 citations Gilles Montalescot, Stephen D. Wiviott et al. The Lancet profile →
  12. Vorapaxar in the Secondary Prevention of Atherothrombotic Events
    2012 656 citations David A. Morrow, Eugene Braunwald et al. New England Journal of Medicine profile →
  13. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
    2007 623 citations Stephen D. Wiviott, Dietmar Trenk et al. Circulation profile →
  14. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
    2019 534 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →
  15. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    2009 500 citations Michelle L. O’Donoghue, Elliott M. Antman et al. The Lancet profile →
  16. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
    2008 498 citations Stephen D. Wiviott, Eugene Braunwald et al. Circulation profile →
  17. Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
    2009 467 citations Jessica L. Mega, Stephen D. Wiviott et al. Circulation profile →
  18. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
    2010 437 citations Jessica L. Mega, Stephen D. Wiviott et al. The Lancet profile →
  19. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
    2017 400 citations Marc S. Sabatine, Lawrence A. Leiter et al. profile →

Peers

Stephen D. Wiviott
Marc S. Sabatine United States
Sabina A. Murphy United States
Kenneth W. Mahaffey United States
A. Michael Lincoff United States
Robert P. Giugliano United States
Aldo P. Maggioni Italy
Colin Baigent United Kingdom
Carolyn H. McCabe United States
Basil S. Lewis Israel
Benjamin M. Scirica United States
Marc S. Sabatine United States
Stephen D. Wiviott
Citations per year, relative to Stephen D. Wiviott Stephen D. Wiviott (= 1×) peers Marc S. Sabatine

Countries citing papers authored by Stephen D. Wiviott

Since Specialization
Citations

This map shows the geographic impact of Stephen D. Wiviott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen D. Wiviott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen D. Wiviott more than expected).

Fields of papers citing papers by Stephen D. Wiviott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen D. Wiviott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen D. Wiviott. The network helps show where Stephen D. Wiviott may publish in the future.

Co-authorship network of co-authors of Stephen D. Wiviott

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen D. Wiviott. A scholar is included among the top collaborators of Stephen D. Wiviott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen D. Wiviott. Stephen D. Wiviott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zimerman, André, Frederick Kamanu, Giorgio Melloni, et al.. (2025). Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease. European Journal of Preventive Cardiology.
2.
Moura, Filipe A., Andrea Bellavia, David D. Berg, et al.. (2024). Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity and Metabolism. 26(10). 4441–4449. 1 indexed citations
3.
Berg, David Van Den, Filipe A. Moura, Benjamin M. Scirica, et al.. (2022). ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal of the American College of Cardiology. 79(9). 962–962. 2 indexed citations
4.
Moura, Filipe A., Itamar Raz, Avivit Cahn, et al.. (2021). Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis. Circulation. 144(Suppl_1).
5.
Oyama, Kazuma, Itamar Raz, Avivit Cahn, et al.. (2020). EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL. Journal of the American College of Cardiology. 75(11). 660–660. 3 indexed citations
6.
Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 139(17). 2022–2031. 534 indexed citations breakdown →
7.
Zelniker, Thomas A., David A. Morrow, Ofri Mosenzon, et al.. (2019). Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. Circulation. 2 indexed citations
8.
Bohula, Erin A., Stephen D. Wiviott, Robert P. Giugliano, et al.. (2017). Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 136(25). 2440–2450. 82 indexed citations
9.
Lau, Emily S., Eugene Braunwald, Sabina A. Murphy, et al.. (2017). Potent P2Y 12 Inhibitors in Men Versus Women. Journal of the American College of Cardiology. 69(12). 1549–1559. 39 indexed citations
10.
Scirica, Benjamin M., David A. Morrow, Elliott M. Antman, et al.. (2012). TIMING AND CLINICAL SETTING OF CARDIOVASCULAR DEATH OR MYOCARDIAL INFARCTION FOLLOWING PCI FOR ACS – OBSERVATIONS FROM THE TRITON-TIMI 38 TRIAL. Journal of the American College of Cardiology. 59(13). E340–E340. 4 indexed citations
11.
12.
Pride, Yuri B., Patricia Tung, Satishkumar Mohanavelu, et al.. (2010). Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression. JACC: Cardiovascular Interventions. 3(8). 806–811. 70 indexed citations
13.
Mega, Jessica L., Tabassome Simon, Jeffrey L. Anderson, et al.. (2009). Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis. Circulation. 120. 12 indexed citations
14.
Diercks, Deborah B., Michael C. Kontos, Anita Y. Chen, et al.. (2009). Utilization and Impact of Pre-Hospital Electrocardiograms for Patients With Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 53(2). 161–166. 193 indexed citations
15.
Wiviott, Stephen D., Eugene Braunwald, Dominick J. Angiolillo, et al.. (2008). Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation. 118(16). 1626–1636. 498 indexed citations breakdown →
16.
Frelinger, Andrew L., Alan D. Michelson, Eugene Braunwald, et al.. (2008). Abstract 3994: Pharmacodynamic Assessment of Platelet Inhibition by Prasugrel versus Clopidogrel in the TRITON-TIMI 38 Trial. Circulation. 118. 2 indexed citations
17.
18.
Wiviott, Stephen D., Eugene Braunwald, Carolyn H. McCabe, et al.. (2007). Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 357(20). 2001–2015. 4421 indexed citations breakdown →
19.
Wiviott, Stephen D., David A. Morrow, Frederick A. Spencer, et al.. (2004). Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4. Journal of the American College of Cardiology. 44(4). 783–789. 74 indexed citations
20.
Wehrenberg, William B., et al.. (1992). Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement.. Endocrinology. 130(3). 1445–1450. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc S. Sabatine Breakdown of academic impact, for papers by Sabina A. Murphy Breakdown of academic impact, for papers by Kenneth W. Mahaffey Breakdown of academic impact, for papers by A. Michael Lincoff Breakdown of academic impact, for papers by Robert P. Giugliano Breakdown of academic impact, for papers by Aldo P. Maggioni Breakdown of academic impact, for papers by Colin Baigent Breakdown of academic impact, for papers by Carolyn H. McCabe Breakdown of academic impact, for papers by Basil S. Lewis Breakdown of academic impact, for papers by Benjamin M. Scirica
Rankless by CCL
2026